首页> 外文期刊>Blood pressure. >Blood pressure variability in hypertensive patients with atrial fibrillation in the VALUE trial
【24h】

Blood pressure variability in hypertensive patients with atrial fibrillation in the VALUE trial

机译:高血压患者在价值试验中的高血压患者血压变异性

获取原文
获取原文并翻译 | 示例
       

摘要

Purpose: Blood pressure variability is associated with traditional cardiovascular risk factors, but little is known about the association with atrial fibrillation. We compared blood pressure variability in patients with and without atrial fibrillation using data from the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial. Materials and methods: The VALUE trial was a randomised-controlled trial of valsartan versus amlodipine in patients with hypertension and high cardiovascular risk, followed for 4.2 years (mean). For the present analysis we included patients with electrocardiogram at baseline and during follow-up, and >3 visits from 6 months onwards. We compared standard deviation {SD) of all blood pressures within each visit averaged across all visits (within-visit variability) and of mean blood pressure at each visit (visit-to-visit variability) in patients with and without atrial fibrillation at baseline. We similarly compared patients who developed non-persistent or persistent atrial fibrillation during follow-up with those who did not, using t-tests, ANOVA and linear regression. Results: Of 15,245 patients in the VALUE trial, 13,827 were eligible for analysis. SD of visit-to-visit systolic blood pressure was not significantly different between patients with and without atrial fibrillation at baseline (mean difference 0.3 mm Hg, p = 0.4), but significantly higher in patients with incident non-persistent or persistent atrial fibrillation during follow-up than in those who never developed atrial fibrillation (differences 1.2 and 1.8 mm Hg, respectively, p-values <0.0001). Associations with non-persistent and persistent atrial fibrillation were confirmed in linear regression models (p-values <0.0001). SD of within-visit systolic blood pressure was not significantly different between patients with and without atrial fibrillation at baseline (p = 0.4) but significantly higher in patients with persistent atrial fibrillation during follow-up (p = 0.04). Conclusion: In patients treated for hypertension, atrial fibrillation was not associated with increased blood pressure variability, but blood pressure variability was higher in those who developed atrial fibrillation during follow-up.
机译:目的:血压变异性与传统的心血管危险因素有关,但对与心房颤动的关联知之甚少。我们使用来自Valsartan抗高血压长期使用评估(价值)试验的数据进行比较患者和无心房颤动的血压变异性。材料和方法:价值试验是高血压患者的Valsartan对氨氯堇属的随机对照试验,持续4.2岁(平均值)。对于本分析,我们包括基线和随访期间心电图的患者,并从6个月开始访问。我们比较了所有血压的标准偏差{SD)在所有访问中的每次访问中的所有血压下降(在访问范围内)和每次访问中的平均血压(参观到参观的变异性),在基线上的心房颤动的患者患者中。我们同样比较了在随访期间,使用T-Tests,Anova和线性回归的人在随访期间比较患者。结果:15,245名患者在价值试验中,13,827名有资格进行分析。在基线(平均差0.3mm Hg,p = 0.4)的患者和没有心房颤动的患者之间没有显着差异(平均差异,p = 0.4),但在发生非持续或持续的心房颤动的患者中显着高随访比在从未开发故觉颤动的人(分别为1.2和1.8 mm Hg,p值<0.0001)。在线性回归模型证实了具有非持续和持续性心房颤动的关联(P值<0.0001)。在基线(P = 0.4)的患者和无心房颤动(P = 0.4)之间的患者之间没有显着差异(P = 0.4),但随访期间持续性心房颤动的患者显着更高(P = 0.04)。结论:在对高血压治疗的患者中,心房颤动与增加的血压变异性无关,但在随访期间开发心房颤动的人中血压变异性更高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号